Summary

The GLP-1 Market is expected to reach USD 49.3 billion by 2024 anticipated to grow at a CAGR of 11.1% during the forecast period 2024-2035.

GLP-1 receptor agonists are a class of medications primarily used to manage blood sugar levels in individuals with type 2 diabetes. Additionally, some GLP-1 agonists can also help treat obesity and related cardiovascular disease. According to the Lancet, 42.4% of adults in the US are obese, and the World Health Organization reports that 4 million people die annually due to obesity. Furthermore, nearly 530 million adults worldwide suffer from diabetes, with 98% of those having type 2 diabetes, and the prevalence of diabetes is expected to increase to nearly 1.3 billion by 2050.
The growing influence of social media, celebrity endorsements, and direct-to-consumer advertising has led to a surge in demand for weight loss and type 2 diabetes treatment solutions, driving innovation and market expansion in this domain. To address this demand, pharmaceutical companies have been developing drugs for type 2 diabetes and body weight management, with GLP-1 agonist drugs emerging as a promising option due to positive clinical trial results and ongoing research and development efforts.
Several GLP-1 drugs targeting obesity and type 2 diabetes have received regulatory approvals globally, including Wegovy, developed by Novo Nordisk, which was approved by the FDA in 2024 for the treatment of serious heart problems in adults with obesity or overweight. The lucrative potential of these drugs has attracted significant attention from both private and public investors, leading to substantial market growth during the forecast period.


Research Coverage:
 This report presents a detailed analysis of the overall market landscape of GLP-1 drugs, along with information on several relevant parameters, such as stage of development (Marketed, Clinical (Phase III, Phase II, Phase I), IND-Enabling and Discovery / Preclinical), type of molecule (biologics and small molecules), active compound used (ecnoglutide, efocipegtrutide, exenatide, froniglutide, isupaglutide, liraglutide, lixisenatide, semaglutide, tirzepatide, utreglutide and other active compounds), GLP-1 agonist (single-agonist, dual-agonist and tri-agonist), route of administration (intraarticular, oral, subcutaneous and sublingual), dosing frequency (single dose, once monthly, once weekly, twice weekly, once daily and twice daily), type of therapy (combination therapy and monotherapy), target indication (Alzheimer’s disease, congenital hyperinsulinism, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH drugs), obesity, obstructive apnea syndrome, Parkinson’s disease, sarcopenia, type 2 diabetes and other target indication) and therapeutic area (genetic disorders, inflammatory disorders, metabolic disorders, neurological disorders, neuromuscular disorders, respiratory disorder and other therapeutic areas). In addition, the chapter provides a detailed list of developers engaged in developing GLP-1 drugs, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters (North America, Europe and Asia-Pacific and Rest of the world) of the players involved in this market space.
 Comprehensive company profiles of leading players developing GLP-1 drugs (shortlisted based on the number of drugs in its pipeline). Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, drug portfolio, recent developments and an informed future outlook.
 Comprehensive assessment of the partnerships signed between stakeholders in the GLP-1 industry, based on several parameters, such as year of partnership, type of partnership, type of molecule, type of partner and most active players (in terms of the number of partnerships signed) and regional distribution of partnership activity in this domain, since 2020
 An in-depth analysis of the factors impacting the overall growth of GLP-1 developers. It also features identification and analysis of key GLP-1 market drivers, potential restraints, emerging opportunities, and existing challenges.
 A comprehensive GLP-1 receptor agonist market forecast analysis in order to estimate the existing market size and future opportunity for GLP-1 companies over the next decade. Based on multiple parameters, such as likely adoption trends, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the global GLP-1 receptor agonist market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
 Comprehensive predictions of the current and future opportunity within the GLP-1 market across different types of molecules, namely biologics and small molecules.
 Comprehensive projection of the current and future opportunity within the GLP-1 receptor agonist market across different active compound used, namely dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds.
 Detailed projection of the current and future opportunity within the GLP-1 industry across different types of GLP-1 agonist drug, namely long-acting GLP-1 agonist and short-acting GLP-1 agonist.
 Detailed projection of the current and future opportunity within the GLP-1 industry across different types of agonists, namely single-agonist, dual-agonist and tri-agonist.
 Detailed projection of the current and future opportunity within the GLP-1 receptor agonist market across different routes of administration, namely oral and parenteral.
 Detailed projection of the current and future opportunity within the GLP-1 market across different target indication, namely Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
 Comprehensive projection of the current and future opportunity within the GLP-1 industry across different key geographical regions, namely North America, Europe, Asia-Pacific and Latin America.
 Detailed projections of the current and future GLP-1 market for the sales of forecasted drugs.
 Detailed projections of the current and future revenues from the sales of drugs developed by the leading players, namely Boehringer Ingelheim, Eli Lilly, Novo Nordisk and other players.

Key Benefits of Buying this Report
 The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
 Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
 The report provides stakeholders with a pulse on the GLP-1 Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
 AstraZeneca
 Biolingus
 Boehringer Ingelheim
 D&D Pharmatech
 Eli Lilly
 Gmax Biopharm
 Hanmi Pharmaceutical
 Innogen
 Novo Nordisk
 PegBio
 Pfizer
 QL Biopharma
 Roche
 Sanofi
 Sciwind Biosciences
 Tonghua Dongbao Pharmaceutical
 Viking Therapeutics
 Vivani
 vTv Therapeutic

ページTOPに戻る

Table of Contents

Table Of Contents

1 BACKGROUND
1.1. Context
1.2. Project Objectives

2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
3.2.2.4. Strategies For Mitigating Foreign Exchange Risk

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4 EXECUTIVE SUMMARY

5 INTRODUCTION
5.1. Overview of the GLP-1 Drug
5.1.1. Challenges Associated with GLP-1 Drugs
5.1.2. Mechanism of Action of GLP-1 Drugs
5.2. Important Facts in GLP-1 Domain
5.3. Future Perspectives

6 MARKET LANDSCAPE: GLP-1 DRUGS
6.1. GLP-1 Drugs: Market Landscape
6.1.1. Analysis by Status of Development
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Active Compound Used
6.1.4. Analysis by Type of Agonist
6.1.5. Analysis by Route of Administration
6.1.6. Analysis by Dosing Frequency
6.1.7. Analysis by Type of Therapy
6.1.8. Analysis by Target Indication
6.1.9. Analysis by Therapeutic Area

6.2. GLP-1 Drugs: Developer Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Headquarters (Country) and Status of Development
6.2.5. Most Active Developers: Analysis by Number of Therapies

7 GLP-1 DRUGS: DETAILED COMPANY PROFILES
7.1. Chapter Overview
7.1.1. AstraZeneca
7.1.1.1. Company Overview
7.1.1.2. Pipeline Portfolio
7.1.1.3. Financial Details
7.1.1.4. Recent Developments and Future Outlook

7.1.2. D&D Pharmatech
7.1.2.1. Company Overview
7.1.2.2. Pipeline Portfolio
7.1.2.3. Financial Details
7.1.2.4. Recent Developments and Future Outlook

7.1.3. Eli Lilly
7.1.3.1. Company Overview
7.1.3.2. Pipeline Portfolio
7.1.3.3. Financial Details
7.1.3.4. Recent Developments and Future Outlook

7.1.4. Novo Nordisk
7.1.4.1. Company Overview
7.1.4.2. Pipeline Portfolio
7.1.4.3. Financial Details
7.1.4.4. Recent Developments and Future Outlook

7.1.5. Pfizer
7.1.5.1. Company Overview
7.1.5.2. Pipeline Portfolio
7.1.5.3. Financial Details
7.1.5.4. Recent Developments and Future Outlook

7.1.6. Sanofi
7.1.6.1. Company Overview
7.1.6.2. Pipeline Portfolio
7.1.6.3. Financial Details
7.1.6.4. Recent Developments and Future Outlook

7.1.7. Tonghua Dongbao Pharmaceutical
7.1.7.1. Company Overview
7.1.7.2. Pipeline Portfolio
7.1.7.3. Financial Details
7.1.7.4. Recent Developments and Future Outlook

7.1.8. Vivani
7.1.8.1. Company Overview
7.1.8.2. Pipeline Portfolio
7.1.8.3. Financial Details
7.2.8.4. Recent Developments and Future Outlook

8 GLP-1 DRUGS: BRIEF COMPANY PROFILES
8.1. Chapter Overview
8.1.1. Biolingus
8.1.1.1. Company Overview
8.1.1.2. Pipeline Portfolio

8.1.2. Boehringer Ingelheim
8.1.2.1. Company Overview
8.1.2.2. Pipeline Portfolio

8.1.3. Gmax Biopharm
8.1.3.1. Company Overview
8.1.3.2. Pipeline Portfolio

8.1.4. Hanmi Pharmaceutical
8.1.4.1. Company Overview
8.1.4.2. Pipeline Portfolio

8.1.5. Innogen
8.1.5.1. Company Overview
8.1.5.2. Pipeline Portfolio

8.1.6. PegBio
8.1.6.1. Company Overview
8.1.6.2. Pipeline Portfolio

8.1.7. QL Biopharma
8.1.7.1. Company Overview
8.1.7.2. Pipeline Portfolio

8.1.8. Roche
8.1.8.1. Company Overview
8.1.8.2. Pipeline Portfolio

8.1.9. Sciwind Biosciences
8.1.9.1. Company Overview
8.1.9.2. Pipeline Portfolio

8.1.10. Viking Therapeutics
8.1.10.1. Company Overview
8.1.10.2. Pipeline Portfolio

8.1.11. vTv Therapeutics
8.1.11.1. Company Overview
8.1.11.2. Pipeline Portfolio
9 PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. GLP-1 Market: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Focus Area
9.3.4. Analysis by Year and Type of Partnership
9.3.5. Most Active Players: Analysis by Number of Partnerships

9.3.6. Analysis by Geography
9.3.6.1. Intercontinental and Intracontinental Deals
9.3.6.2. Local and International Deals

10 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
10.1. Chapter Overview
10.2. Market Drivers
10.3. Market Restraints
10.4. Market Opportunities
10.5. Market Challenges
10.6. Conclusion

11 GLOBAL GLP-1 MARKET
11.1. Assumptions and Methodology
11.2. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
11.2.1. Scenario Analysis
11.2.1.1. Conservative Scenario
11.2.1.2. Optimistic Scenario

11.2.2. Key Market Segmentations

12 GLP-1 MARKET, BY TYPE OF MOLECULE
12.1. Assumptions and Methodology
12.2. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
12.2.1. GLP-1 Market for Biologics, till 2035
12.2.2. GLP-1 Market for Small Molecules, till 2035

12.3. Data Triangulation and Validation

13 GLP-1 MARKET, BY ACTIVE COMPOUND USED
13.1. Assumptions and Methodology
13.2. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
13.2.1. GLP-1 Market for Dulaglutide, till 2035
13.2.2. GLP-1 Market for Liraglutide, till 2035
13.2.3. GLP-1 Market for Orforglipron, till 2035
13.2.4. GLP-1 Market for Retatrutide, till 2035
13.2.5. GLP-1 Market for Semaglutide, till 2035
13.2.6. GLP-1 Market for Survodutide, till 2035
13.2.7. GLP-1 Market for Tirzepatide, till 2035
13.2.8. GLP-1 Market for Other Active Compounds, till 2035

13.3 Data Triangulation and Validation

14 GLP-1 MARKET, BY TYPE OF GLP-1 AGONIST DURGS
14.1. Assumptions and Methodology
14.2. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drugs, 2020, 2024 and 2035
14.2.1. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035
14.2.2. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035

14.3. Data Triangulation and Validation

15 GLP-1 MARKET, BY GLP-1 AGONIST
15.1. Assumptions and Methodology
15.2. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
15.2.1. GLP-1 Market for Single-agonist, till 2035
15.2.2. GLP-1 Market for Dual-agonist, till 2035
15.2.3. GLP-1 Market for Tri-agonist, till 2035

15.3. Data Triangulation and Validation

16 GLP-1 MARKET, BY ROUTE OF ADMINISTRATION
16.1. Assumptions and Methodology
16.2. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
16.2.1. GLP-1 Market for Oral Route, till 2035
16.2.2. GLP-1 Market for Parenteral Route, till 2035

16.3. Data Triangulation and Validation

17 GLP-1 MARKET, BY TARGET INDICATION
17.1. Assumptions and Methodology
17.2. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
17.2.1. GLP-1 Market for Alzheimer’s Disease, till 2035
17.2.2. GLP-1 Market for Non-Alcoholic Steatohepatitis, till 2035
17.2.3. GLP-1 Market for Obesity, till 2035
17.2.4. GLP-1 Market for Sleep Apnea, till 2035
17.2.5. GLP-1 Market for Type 2 Diabetes, till 2035

17.3. Data Triangulation and Validation

18 GLP-1 MARKET, BY GEOGRAPHY
18.1. Assumptions and Methodology
18.2. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
18.2.1. GLP-1 Market in North America, till 2035
18.2.2. GLP-1 Market in Europe, till 2035
18.2.3. GLP-1 Market in Asia-Pacific, till 2035
18.2.4. GLP-1 Market in Latin America, till 2035
18.3. Data Triangulation and Validation

19 GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS
19.1. Chapter Overview
19.2. Approved GLP-1 Drugs: Sales Forecast
19.2.1. Feisumei (Benaglutide) Sales Forecast
19.2.2. Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast
19.2.3. Mounjaro (Tirzepatide) Sales Forecast
19.2.4. Ozempic (Semaglutide Subcutaneous) Sales Forecast
19.2.5. Rybelsus (Semaglutide Oral) Sales Forecast
19.2.6. Saxenda (Liraglutide) Sales Forecast
19.2.7. Trulicity (Dulaglutide) Sales Forecast
19.2.8. Victoza (Liraglutide) Sales Forecast
19.2.9. Wegovy (Semaglutide Subcutaneous) Sales Forecast
19.2.10. XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast
19.2.11. Zepbound (Tirzepatide) Sales Forecast
19.3. Phase III GLP-1 Drugs: Sales Forecast
19.3.1. GMA102 / Glutazumab Sales Forecast
19.3.2. JY09 Sales Forecast
19.3.3. LY3298176 / Tirzepatide Sales Forecast
19.3.4. Mazdutide / LY3305677/ IBI-362 Sales Forecast
19.3.5. Orforglipron / LY3502970 Sales Forecast
19.3.6. PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast
19.3.7. Retatrutide / LY3437943 Sales Forecast
19.3.8. Semaglutide Oral Sales Forecast
19.3.9. Semaglutide Subcutaneous Sales Forecast
19.3.10. Survodutide / BI 456906 Sales Forecast
19.3.11. XW003 / Ecnoglutide Sales Forecast
19.3.12. YN011-isupaglutide Sales Forecast
20 GLP-1 MARKET, BY LEADING DRUG DEVELOPERS
20.1. Chapter Overview
20.2. GLP-1 Market: Distribution by Leading Drug Developers, 2020 (USD Million)
20.3. GLP-1 Market: Distribution by Leading Drug Developers, 2024 (USD Million)
20.4. GLP-1 Market: Distribution by Leading Drug Developers, 2035 (USD Million)
21 APPENDIX 1: TABULATED DATA
22 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 6.1. List of GLP-1 Drugs
Table 6.2. List of GLP-1 Drug Developers
Table 7.1. AstraZeneca: Pipeline Portfolio
Table 7.2. AstraZeneca: Recent Developments and Future Outlook
Table 7.3. D&D Pharmatech: Pipeline Portfolio
Table 7.4. D&D Pharmatech: Recent Developments and Future Outlook
Table 7.5. Eli Lilly: Pipeline Portfolio
Table 7.6. Eli Lilly: Recent Developments and Future Outlook
Table 7.7. Novo Nordisk: Pipeline Portfolio
Table 7.8. Novo Nordisk: Recent Developments and Future Outlook
Table 7.9. Pfizer: Pipeline Portfolio
Table 7.10. Pfizer: Recent Developments and Future Outlook
Table 7.11. Sanofi: Pipeline Portfolio
Table 7.12. Sanofi: Recent Developments and Future Outlook
Table 7.13. Tonghua Dongbao Pharmaceutical: Pipeline Portfolio
Table 7.14. Tonghua Dongbao Pharmaceutical: Recent Developments and Future Outlook
Table 7.15. Vivani: Pipeline Portfolio
Table 7.16. Vivani: Recent Developments and Future Outlook
Table 8.1. Biolingus: Pipeline Portfolio
Table 8.2. Boehringer Ingelheim: Pipeline Portfolio
Table 8.3. Gmax Biopharm: Pipeline Portfolio
Table 8.4. Hanmi Pharmaceutical: Pipeline Portfolio
Table 8.5. PegBio: Pipeline Portfolio
Table 8.6. QL Biopharma: Pipeline Portfolio
Table 8.7. Roche: Pipeline Portfolio
Table 8.8. Sciwind Biosciences: Pipeline Portfolio
Table 8.9. Viking Therapeutics: Pipeline Portfolio
Table 8.10. vTv Therapeutics: Pipeline Portfolio
Table 9.1. GLP-1 Drug Market: List of Partnerships and Collaborations, Since 2020
Table 11.1. List of GLP-1 Drugs Forecasted
Table 21.1. GLP-1 Drugs: Distribution by Status of Development
Table 21.2. GLP-1 Drugs: Distribution by Type of Molecule
Table 21.3. GLP-1 Drugs: Distribution by Active Compound Used
Table 21.4. GLP-1 Drugs: Distribution by Type of Agonist
Table 21.5. GLP-1 Drugs: Distribution by Route of Administration
Table 21.6. GLP-1 Drugs: Distribution by Dosing Frequency
Table 21.7. GLP-1 Drugs: Distribution by Type of Therapy
Table 21.8. GLP-1 Drugs: Distribution by Target Indication
Table 21.9. GLP-1 Drugs: Therapeutic Area
Table 21.10. GLP-1 Drugs Developer: Distribution by Year of Establishment
Table 21.11. GLP-1 Drugs Developer: Distribution by Company Size
Table 21.12. GLP-1 Drugs Developer: Distribution by Location of Headquarters
Table 21.13. GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development
Table 21.14. Most Active Developers: Distribution by Number of Drugs
Table 21.15. AstraZeneca: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Table 21.16. D&D Pharmatech: Annual Revenues, FY 2021-FY 2023 (KRW Billion)
Table 21.17. Eli Lilly: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Table 21.18. Novo Nordisk: Annual Revenues, FY 2021-FY 2023 (DKK Billion)
Table 21.19. Pfizer: Annual Revenues, FY 2021-FY 2023 (USD Billion)
Table 21.20. Sanofi: Annual Revenues, FY 2021-FY 2023 (EUR Billion)
Table 21.21. Tonghua Dongbao Pharmaceutical: Annual Revenues, FY 2021-FY 2023 (RMB Billion)
Table 21.22. Partnerships and Collaborations: Distribution by Year of Partnership
Table 21.23. Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.24. Partnerships and Collaborations: Distribution by Focus Area
Table 21.25. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 21.26. Most Active Players: Distribution by Number of Partnerships
Table 21.27. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals
Table 21.28. Partnerships and Collaborations: Distribution by Local and International Deals
Table 21.29. Global GLP-1 Market, Historical Trends (2020-2023) (USD Billion)
Table 21.30. Global GLP-1 Market, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario, (USD Billion)
Table 21.31. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
Table 21.32. GLP-1 Market for Biologics, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.33. GLP-1 Market for Small Molecule, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.34. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
Table 21.35. GLP-1 Market for Dulaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.36. GLP-1 Market for Liraglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.37. GLP-1 Market for Orforglipron, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.38. GLP-1 Market for Retatrutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.39. GLP-1 Market for Semaglutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.40. GLP-1 Market for Survodutide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.41. GLP-1 Market for Tirzepatide, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.42. GLP-1 Market for Other Active Compounds, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.43. GLP-1 Market: Distribution by Type of GLP-1 Agonist Drug, 2020, 2024 and 2035
Table 21.44. GLP-1 Market for Long-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.45. GLP-1 Market for Short-acting GLP-1 Agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.46. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
Table 21.47. GLP-1 Market for Single-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.48. GLP-1 Market for Dual-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.49. GLP-1 Market for Tri-agonist, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.50. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
Table 21.51. GLP-1 Market for Oral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.52. GLP-1 Market for Parenteral Route, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.53. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
Table 21.54. GLP-1 Market for Alzheimer’s Disease, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.55. GLP-1 Market for Non-alcoholic Steatohepatitis, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.56. GLP-1 Market for Obesity, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.57. GLP-1 Market for Sleep Apnea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.58. GLP-1 Market for Type 2 Diabetes, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.59. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
Table 21.60. GLP-1 Market in North America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.61. GLP-1 Market in US, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.62. GLP-1 Market in Canada, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.63. GLP-1 Market in Europe, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.64. GLP-1 Market in Germany, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.65. GLP-1 Market in UK, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.66. GLP-1 Market in France, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.67. GLP-1 Market in Italy, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.68. GLP-1 Market in Spain, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.69. GLP-1 Market in Asia Pacific, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.70. GLP-1 Market in China, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.71. GLP-1 Market in Japan, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.72. GLP-1 Market in Australia, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.73. GLP-1 Market in South Korea, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.74. GLP-1 Market in Latin America, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.75. GLP-1 Market in Brazil, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.76. GLP-1 Market in Argentina, Forecasted Estimates, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.77. Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.78. Approved GLP-1 Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.79. Approved GLP-1 Drug, Mounjaro (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.80. Approved GLP-1 Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.81. Approved GLP-1 Drug, Rybelsus (Semaglutide Oral) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.82. Approved GLP-1 Drug, Saxenda (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.83. Approved GLP-1 Drug, Trulicity (Dulaglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.84. Approved GLP-1 Drug, Victoza (Liraglutide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.85. Approved GLP-1 Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.86. Approved GLP-1 Drug, XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.87. Approved GLP-1 Drug, Zepbound (Tirzepatide) Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.88. Phase III GLP-1 Drug, GMA102 / Glutazumab Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.89. Phase III GLP-1 Drug, JY09 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.90. Phase III GLP-1 Drug, LY3298176 / Tirzepatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.91. Phase III GLP-1 Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.92. Phase III GLP-1 Drug, Orforglipron / LY3502970 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.93. Phase III GLP-1 Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.94. Phase III GLP-1 Drug, Retatrutide / LY3437943 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.95. Phase III GLP-1 Drug, Semaglutide Oral Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.96. Phase III GLP-1 Drug, Semaglutide Subcutaneous Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.97. Phase III GLP-1 Drug, Survodutide / BI 456906 Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.98. Phase III GLP-1 Drug, XW003 / Ecnoglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.99. Phase III GLP-1 Drug, YN011-isupaglutide Sales Forecast, till 2035, Conservative, Base and Optimistic Scenario (USD Billion)
Table 21.100. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020, Conservative, Base and Optimistic Scenario (USD Billion))
Table 21.101. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2024, Conservative, Base and Optimistic Scenario (USD Billion))
Table 21.102. GLP-1 Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035, Conservative, Base and Optimistic Scenario (USD Billion))